Chung-Ming (CM) Hsieh

VP, Research Protein Therapeutics
Gilead Sciences

​

Chung-Ming (CM) Hsieh currently serves as Vice President of Research Protein Therapeutics at Gilead Sciences, a role he has held since 2022. Dr. Hsieh is a seasoned leader in biologic drug discovery, with extensive experience guiding programs from early-stage identification through Investigational New Drug (IND) applications. Before joining Gilead, he held positions of increasing responsibility at Merck (2017–2022) and AbbVie (2002–2017). Throughout his career, Dr. Hsieh has directed teams responsible for developing platform technologies, such as in vitro mRNA and yeast display systems, to advance antibody discovery, protein engineering, and developability assessments. He has contributed to advancing biologic candidates from discovery to preclinical development across a range of therapeutic areas, including oncology, immunology, virology, neuroscience, and cardiometabolic diseases. Notably, he has been involved in projects such as lutikizumab for autoimmune disorders and elezanumab for spinal cord injury. Dr. Hsieh earned his doctoral degree in Biological Sciences from the Harvard School of Public Health and completed postdoctoral training at Harvard Medical School and Brigham and Women’s Hospital in Boston. He obtained his Bachelor of Science in Zoology from National Taiwan University.

 

Speech title & Synopsis

Panel Discussion 1: Business Development & Licensing - Critical Exit Strategy for New Venture

Panelist